Compare Aehr Test Systems (AEHR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs Sana Biotechnology Inc — how do they compare? Aehr Test Systems trades at $66.71 (market cap $2.11B), while Sana Biotechnology Inc trades at $3.95 (market cap $1.15B). The key difference: Aehr Test Systems is the larger of the two by market cap, and Aehr Test Systems is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AEHR | SANA | |
|---|---|---|
Market Cap | $2.11B | $1.15B |
Sector | Technology | Health |
52-Week High | $116.58 | $5.92 |
52-Week Low | $13.29 | $2.68 |
Enterprise Value | $2.08B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
